Drugfield Pharmaceuticals

What Drugfield Pharmaceuticals does

Drugfield Pharmaceuticals Limited is a Nigerian pharmaceutical manufacturer founded in 1991 and headquartered at Lynson Chemical Avenue, Sango Ota, Ogun State. The company operates a multi-dosage manufacturing platform producing approximately 60+ generic pharmaceutical products across tablets, capsules, syrups, creams, ointments, gels, eye/ear drops, injections, and intravenous infusions, spanning antibiotics, antifungals, antimalarials, analgesics, cardiovascular drugs, ophthalmic preparations, dermatological products, IV solutions, and specialty lines. Its flagship product is Chlorxy-G Gel (Chlorhexidine digluconate 7.1%), an umbilical cord antiseptic for newborns, for which Drugfield became the first African and second global manufacturer following NAFDAC approval in March 2014, developed in partnership with PATH and USP-PQM and admitted into the World Chlorhexidine Working Group the same year.

The company reaches customers through a hybrid go-to-market model combining 13 company-owned depots across Nigeria, a network of approximately 34 third-party distributors covering all major Nigerian states, direct sales to pharmacies and healthcare institutions, and an active export business to seven African countries (Ghana, Zambia, Niger, Mozambique, Republic of Benin, Mali, Cote D'Ivoire), with product registration ongoing in Togo and Senegal. Revenue is generated through one-time unit-priced product sales, denominated in naira domestically and US dollars for export orders at $0.32–$5.30 per unit ex-factory. Customer segments span healthcare consumers via retail pharmacies, government and public health institutions (including public-sector procurement such as the First Lady of Ghana's maternal-newborn initiative), and intermediary distributors. Pricing is transactional (Pay-as-you-go) with no disclosed subscription or licensing model.

Operationally, Drugfield runs as a privately held, family-founded Nigerian limited company with 501–1,000 employees, no disclosed institutional capital, no parent company, and no subsidiaries. The business model is asset- and distribution-heavy rather than technology- or data-driven: the competitive position rests on manufacturing breadth, regulatory standing (NAFDAC registration across a wide SKU base, WHO-aligned quality standards, 2019 NAFDAC Award), and physical distribution scale across Nigeria and West/East/Southern Africa.

Name

Drugfield Pharmaceuticals

Legal name

Drugfield Pharmaceuticals Limited

Website

https://drugfieldpharma.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Drugfield Pharmaceuticals is a Nigerian multi-dosage generic drug manufacturer founded in 1991, producing antibiotics, antifungals, antimalarials, analgesics, and IV solutions via 13 domestic depots, 34 distributors, and exports to seven African countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Antibiotic production
• Antimalarial drugs
• Pharmaceutical distribution

Headquarters

HQ city

Sango Otta

HQ country

Nigeria

HQ region

Africa

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Drugfield generates revenue through the sale of its broad portfolio of generic pharmaceutical products including antibiotics, antifungals, antimalarials, analgesics, cardiovascular drugs, ophthalmic preparations, dermatological products, and IV solutions. Products are sold domestically through distributors and depots, and exported to African markets.
2. Export Business: Drugfield exports pharmaceutical products to Ghana, Zambia, Niger, Mozambique, Republic of Benin, Mali and other countries. Export pricing is listed in USD for international customers.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Drugfield Pharmaceuticals manufactures and distributes a broad portfolio of multi-dosage generic pharmaceutical products across therapeutic categories including antibiotics, antifungals, antimalarials, analgesics/anti-inflammatories, cardiovascular drugs (antihypertensives, antidiabetics, lipid-lowering agents), ophthalmic preparations, dermatological creams, and intravenous solutions. Products are sold in Nigeria through 13 company-owned depots and approximately 34 third-party distributors and exported to multiple African countries including Ghana, Zambia, Niger, Mozambique, Republic of Benin, and Mali.

Product overview

Drugfield Pharmaceuticals Ltd is a Nigerian pharmaceutical manufacturing company established in 1991, producing multi-dosage pharmaceutical products across multiple therapeutic categories. The company's product portfolio includes: antibiotics (Biocine, Coptrine, Dramoxilin, Ciflaxin, Compi-Clox), antifungals (Flucamed, Mycoten, Ketofung, Betrosil), anti-malarials (Drutemal-Plus, Metafizin, Dupridox), analgesics/anti-inflammatories (Drugamol, Diclofenac, NeuroGesic, NeuroXicam, Ibuprofen), cardiovascular drugs (Kuinopril, Kuinopril-Plus, Glucoform, Lipistatin), ophthalmic products (Druphagan, Druphagan Plus, Betadrone-N, Chloramphenicol Eye Drops), topical preparations (Drunalog-GE, Neo-presol, Hemoplus, Mepisan, Hydrocortisone), intravenous solutions (Dextrose, Metrodine, Normal Saline), respiratory/cough preparations (Cofepront, Coflax), and specialty products including Chlorxy-G Gel (umbilical cord antiseptic). The company operates from Sango Otta, Ogun State, with distribution across 13 depots nationwide.

Differentiator

Problem solved

Functional benefit

Brands

• Chlorxy-G: Chlorhexidine Digluconate 7.1% antiseptic gel for umbilical cord care in newborns - a flagship product and the first locally manufactured Chlorhexidine gel in Africa
• Biocoten
• Mycoten
• Flucamed
• Neurogesic
• Drutemal
• Caldopa
• Glucoform
• Kuinopril
• Betadrone-N
• Drugamol

Products and services

• Chlorxy-G Gel Chlorhexidine Digluconate 7.1% antiseptic gel for umbilical cord care in newborn babies, developed in response to WHO recommendation to reduce neonatal mortality. Sold via distributors, depots, and African export markets.
• Flucamed (Fluconazole) Oral antifungal capsules and powder for oral suspension for treating cryptococcosis, candidiasis, and dermatomycosis. Targeted at patients with fungal infections, supplied via pharmacies and distributors.
• Dramoxilin (Amoxycillin) Antibiotic capsules and dry syrup for treating bacterial infections, supplied to pharmacies and healthcare institutions.
• Coptrine (Sulphamethoxazole + Trimethoprim) Antibiotic tablets and suspension for treating bacterial infections.
• Biocine (Lincomycin) Antibiotic capsules and syrup for treating bacterial infections.
• Ciflaxin (Ciprofloxacin) Antibiotic caplets, eye/ear drops, and infusion for treating various bacterial infections.
• Mycoten (Clotrimazole) and Mycoten Plus (Clotrimazole + Clindamycin) Antifungal cream, solution, powder, vaginal cream and vaginal tablets for treating fungal infections. Mycoten Plus is a combination antifungal/antibacterial vaginal cream and tablets for vaginal candidiasis and bacterial vaginosis.
• Ketofung (Ketoconazole) Broad spectrum antifungal caplets and cream for treating fungal infections.
• Drutemal-Plus (Artemether + Lumefantrine) Anti-malaria tablets and oral suspension for treating malaria.
• Metafizin (Sulphamethoxypyrazine + Pyrimethamine) Anti-malaria tablet for intermittent preventive treatment of malaria in pregnancy and treatment of malaria caused by various Plasmodium species.
• Diclofenac (Capsules, Eye Drops, Gel) Analgesic/anti-inflammatory capsules, eye drops, and gel for pain and inflammation management.
• NeuroGesic and NeuroXicam (Piroxicam) Analgesic greaseless ointment (and extra formulation) for musculoskeletal pain relief plus NSAID gel and capsule for treating musculoskeletal disorders, osteoarthritis, and muscular pain.
• Drugamol (Paracetamol) Analgesic/anti-pyretic tablets, injection, and syrup for pain and fever management.
• Druphagan and Druphagan Plus Eye Drops Anti-glaucoma eye drops containing Brimonidine Tartrate 0.2% (Druphagan) and Brimonidine Tartrate 0.2% with Timolol 0.5% (Druphagan Plus) for lowering intraocular pressure.
• Betadrone-N Eye/Ear Drops Anti-inflammatory/antibiotic eye and ear drops for treating ocular and otic infections.
• Chloramphenicol Eye/Ear Drops and Eye Ointment Antibiotic eye and ear drops and ointment for treating bacterial conjunctivitis and superficial ear infections.
• Kuinopril (Lisinopril) and Kuinopril-Plus (Lisinopril + Hydrochlorothiazide) Anti-hypertensive tablets for treating essential hypertension, congestive heart failure, and diabetic nephropathy; the Plus variant combines Lisinopril with Hydrochlorothiazide for managing essential hypertension.
• Caldopa (Methyldopa) and Drulovask (Amlodipine) Anti-hypertensive tablets (Methyldopa-based and Amlodipine-based) for managing hypertension.
• Glucoform (Metformin) Anti-diabetic caplets for treating non-insulin dependent diabetes, especially in overweight patients.
• Lipistatin (Atorvastatin) Anti-hyperlipidaemia tablets for treating and preventing cardiovascular disease.
• Dextrose Injection (5%, 10%, 50%) Dextrose solutions for treating carbohydrate and fluid depletion and severe hypoglycaemia, supplied to hospitals and clinics.
• Metrodine (Metronidazole) Intravenous Infusion Intravenous infusion for preventing and treating anaerobic bacterial infections, supplied to healthcare institutions.
• Cofepront Syrup and Coflax Cough Syrup Antitussive/expectorant syrups containing Salbutamol, Guaifenesin, Bromhexine and Menthol (Cofepront) plus adult and children formulations (with and without codeine) of Coflax for treating productive cough.
• Drunalog-GE Cream Topical cream containing Econazole Nitrate, Triamcinolone Acetonide, and Gentamicin for treating inflammatory dermatoses and bacterial/fungal skin infections.
• Neo-Presol Lotion Anti-acne lotion containing Methyl Prednisolone, Sulphur, and Neomycin for treating acne vulgaris and rosacea.
• Hemoplus Cream Cream containing Chlorhexidine, Hydrocortisone, and Gentamicin for treating internal and external hemorrhoids.
• Hydrocortisone Cream Topical anti-inflammatory cream for treating contact eczema, seborrhoeal eczema, and psoriasis.
• Becomex Injection, Mutrovite Drops/Syrup, and Haepler Blood Capsules/Tonic Multivitamin injection (B-complex vitamins), pediatric multivitamin drops and syrup, and haematinic capsules/tonic containing iron and B vitamins for nutritional supplementation.
• Compi-Clox (Ampicillin + Cloxacillin) Combination antibiotic capsules, dry syrup, and neonatal drops for bacterial infections in adults and neonates.
• Export Business (Pharmaceutical Products to African Markets) Direct export of pharmaceutical products to Ghana, Zambia, Niger, Mozambique, Republic of Benin, Mali, and other African countries with USD-denominated ex-factory pricing. Products registered in Ghana, Republic of Benin, Niger, Cote D'Ivoire, and Zambia; registration ongoing in Togo and Senegal.

Quantifiable outcome

• First company in Africa to manufacture WHO-recommended Chlorhexidine digluconate 7.1% gel for umbilical cord care
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• World Chlorhexidine Working Group (CWG)coreStrategic or Co-development Partner · 1 May 2014Drugfield was formally admitted into the World Chlorhexidine Working Group (CWG) in Washington D.C USA in May 2014. The CWG is a global body focused on promoting the use of Chlorhexidine for umbilical cord care to reduce neonatal mortality.
• PATH (Program for Appropriate Technology in Health)coreStrategic or Co-development Partner · 1 March 2014Drugfield partnered with PATH to develop qualitative local capacity for the manufacture of Chlorhexidine digluconate 7.1% gel for umbilical cord care in newborn babies. PATH provided technical support and validation for the product development.
• USP-PQM (United States Pharmacopeia: Promoting the Quality of Medicines)coreStrategic or Co-development Partner · 1 March 2014Partnership with USP-PQM teams in developing local capacity for the manufacture of Chlorhexidine digluconate 7.1%. USP-PQM provided technical assistance and quality standards verification.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Cipla: Indian-headquartered global pharmaceutical company with strong presence in African generic pharmaceutical markets, particularly in antimalarials and ARVs. Competes with Drugfield in African tenders and exports.

Direct peers

• Fidson Healthcare: Nigerian pharmaceutical manufacturer of generic drugs across therapeutic categories including antibiotics, antimalarials, and cardiovascular drugs. Comparable in size, manufacturing footprint, and target market to Drugfield.
• CHI Pharmaceuticals: Nigerian pharmaceutical manufacturer and Drugfield distribution partner. Operates in the same generic pharmaceutical manufacturing and distribution space in Nigeria.
• Emzor Pharmaceuticals: A leading Nigerian pharmaceutical manufacturer producing antibiotics, analgesics, antimalarials, and other generic medicines across multiple dosage forms. Direct competitor in the same Nigerian generic pharma manufacturing space with similar distribution scale.
• May & Baker Nigeria: One of Nigeria's oldest pharmaceutical manufacturers producing generics, infusions, and OTC products. Direct competitor in Nigerian pharmaceutical manufacturing with overlapping therapeutic portfolio.
• Swipha (Sterling Pharma): Nigerian pharmaceutical manufacturer of generic medicines including antibiotics, antiparasitics, and dermatologicals. Comparable scale and product mix to Drugfield.

Broad incumbents

• Aspen Pharmacare: South Africa's largest pharmaceutical manufacturer with extensive African distribution and a portfolio spanning generics, branded pharma, and consumer health. Comparable in pan-African pharmaceutical scale and emerging-market focus.
• GSK Nigeria: Multinational pharmaceutical company with Nigerian operations producing antibiotics, analgesics, and consumer health products. Competes with Drugfield in overlapping therapeutic categories.
• Sanofi Nigeria: Multinational pharmaceutical company's Nigerian operations producing branded and generic medicines. Comparable in therapeutic categories but with broader global backing and deeper capital.

Regional players

• Pharmacare Limited: South African pharmaceutical manufacturer focused on generic and OTC medicines across Africa. Comparable in generic pharmaceutical manufacturing and pan-African distribution, though primarily serving Southern Africa.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/DrugfieldNGR
• YouTubeyoutube.com/channel/UCxCJmvTaP748nPWe63jaKuA
• Facebookfacebook.com/drugfieldpharma
• LinkedInlinkedin.com/company/drugfield-pharmaceuticals-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drugfield Pharmaceuticals